Loading...
Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer
Gemcitabine is the first-line treatment for locally advanced and metastatic gallbladder cancer (GBC), but poor gemcitabine response is universal. Here, we utilize a genome-wide CRISPR screen to identify that loss of ELP5 reduces the gemcitabine-induced apoptosis in GBC cells in a P53-dependent manne...
Na minha lista:
| Udgivet i: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889377/ https://ncbi.nlm.nih.gov/pubmed/31792210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13420-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|